Jim Flynn is the Managing Partner of Deerfield Management, a healthcare-focused investment firm overseeing approximately $16 billion in assets. In this episode, hosts Michael Mauboussin and Tano Santos speak with Jim about his path from studying biology and economics to leading one of the industry's most distinctive healthcare investment platforms. Jim explains how Deerfield evolved from a public-equity-focused firm into an organization spanning public markets, private investments, venture creation, drug development, data science, and philanthropy. The conversation examines the challenges of healthcare investing, the importance of probabilistic thinking, the role of artificial intelligence in healthcare delivery and drug discovery, and Deerfield's approach to identifying opportunities across the healthcare ecosystem. Jim also shares insights on senior housing, healthcare innovation, regulatory dynamics, and the skills required for the next generation of healthcare investors, and much more! Key Topics: ● Jim Flynn's background in biology, economics, and early investing influences (2:27) ● Lessons from working in corporate development and understanding business operations (4:30) ● Joining Deerfield and the evolution from analyst to firm leader (7:52) ● Expanding Deerfield beyond public equities into venture, private investments, and philanthropy (10:36) ● Building a flexible healthcare investment platform across market cycles (13:58) ● The Melinta case study and transforming a distressed investment into an operating success (14:32) ● Artificial intelligence and its potential impact on healthcare delivery and diagnosis (18:52) ● AI adoption challenges and the role of healthcare institutions in driving change (22:13) ● Why proprietary healthcare data creates durable investment advantages (25:50) ● The creation of Deerfield Discovery and Development and CURE (27:12) ● Cross-pollination between public and private investing at Deerfield (31:05) ● The NewAmsterdam Pharma (NewValent) case study from concept to multibillion-dollar company (33:08) ● Investing in senior housing and demographic-driven opportunities (36:20) ● Evaluating healthcare policy, drug pricing, and regulatory risks through a long-term lens (40:16) ● Skills and characteristics needed for future healthcare investors (43:09) ● What worries and motivates Jim Flynn as a healthcare investor (44:30) ● Deerfield's investment process, team structure, and reducing analytical bias (46:53) ● Personal healthcare practices, longevity, and access to medical information (51:25) ● And much more! Mentioned in this Episode: ● Deerfield Management ● Alpharma ● Kidder Peabody ● GlaxoSmithKline ● Sanofi ● Hospital for Special Surgery ● Brookdale Senior Living ● OpenAI ● ChatGPT ● GRAIL ● Food and Drug Administration Thanks for Listening! Be sure to subscribe on Apple, Google, Spotify, or wherever you get your podcasts. And feel free to drop us a line at [email protected]. Follow the Heilbrunn Center on social media on Instagram, LinkedIn, and more!